A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
about
In Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid LibrariesPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsCombination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancerCell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cellsA BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternativesComparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles.A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancerFull preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.Variable Heavy Chain Domain Derived from a Cell-Penetrating Anti-DNA Monoclonal Antibody for the Intracellular Delivery of Biomolecules.Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.Detection and quantitation of glutamate carboxypeptidase II in human blood.Adding Functions to Biomaterial Surfaces through Protein Incorporation.Highly sensitive electrochemiluminescence detection of a prostate cancer biomarkerDesign, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells
P2860
Q26782129-294E78A5-7747-49F5-9645-AE90E63B196AQ27339832-A65A71F6-F03A-4B84-B639-2D92B8BAF6F1Q30557008-A93404EA-C652-4438-A486-5E83C3264749Q33589310-CC76F838-81BC-4007-A2D1-8C2EDB2A3D52Q33632095-9832CC30-B1DB-4A39-8326-DB1F444C2CFFQ34473460-ACB6FB6E-23D8-4EB0-BA46-EFC4A829B71FQ35282416-1C3F869C-84BA-4FDA-AEFC-20555B755FB4Q35722917-1DA37764-BC7B-4F0D-AC55-D8B91F36EAF9Q37644883-1732D4F2-BA67-4B64-AEB4-562C9322EA8CQ37706857-F133CCE0-AD59-4964-91A2-E55E5B8BD19CQ38784721-1D0408AA-1EA3-4C59-B7B9-E33EADCE21F1Q39017235-186621D4-5469-4294-AB0A-62AD278C9280Q50743140-45E6923E-1392-4B7F-A3C1-7E554514748DQ51743830-B75BF093-D920-4F5D-A350-1CBAF12863F0Q52768383-45F4841D-94C6-4041-9942-661DB252D41DQ53100671-48B47B4C-9279-47FA-95A5-9E3A4043593DQ55872216-13CE811A-9536-42F6-B060-70210CC57C04Q59134014-2AD802EF-81F8-4811-9463-7DC306DF6125
P2860
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A single-chain fragment agains ...... reagents for prostate cancer.
@en
A single-chain fragment agains ...... reagents for prostate cancer.
@nl
type
label
A single-chain fragment agains ...... reagents for prostate cancer.
@en
A single-chain fragment agains ...... reagents for prostate cancer.
@nl
prefLabel
A single-chain fragment agains ...... reagents for prostate cancer.
@en
A single-chain fragment agains ...... reagents for prostate cancer.
@nl
P2093
P50
P1476
A single-chain fragment agains ...... c reagents for prostate cancer
@en
P2093
E Bombardieri
M Colombatti
M Mortarino
S Canevari
P304
P356
10.1016/J.EJCA.2013.01.024
P50
P577
2013-02-20T00:00:00Z